Postnatal changes in response to adenosine and adenine nucleotides in rat duodenum.
1. The effects of adenosine and adenine nucleotides were studied in rat duodenum from postnatal day 1 to day 70. The mechanical activity of duodenal segments was recorded through an isotonic transducer connected to a polygraphic recorder. 2. In rat duodenal segments, adenosine-5'-triphosphate (ATP, 10(-4) M) and adenosine-5'-diphosphate (ADP, 10(-4) M) produced a contractile response on postnatal day 1. This response increased with age, peaking on day 7, followed by a gradual decrease and was non-existent by day 21. In contrast, a relaxant response to ATP and ADP was apparent on day 21, and continued to increase up to day 70. 3. The contraction caused by ATP was inhibited by indomethacin or the P2y-purinoceptor antagonist, reactive blue-2 but not by tetrodotoxin or hyoscine. Thus, it may be mediated by production of prostaglandin through the P2y-purinoceptor. The relaxation produced by ATP was inhibited by reactive blue-2 but not by tetrodotoxin, guanethidine or the P1-purinoceptor antagonist, 8-phenyltheophylline indicating that ATP acts on smooth muscle directly through the P2y-purinoceptor. The pD2 for the contractile response to ATP was 5.15 on day 7 and that for the relaxant response, 6.64 on day 70. 4. Adenosine (10(-4) M) and adenosine-5'-monophosphate (AMP, 10(-4) M) elicited no response before day 14. On day 14, both adenosine and AMP produced a small relaxant response which increased with age. The relaxation produced by adenosine was inhibited by 8-phenyltheophylline but not by tetrodotoxin or guanethidine, indicating that it is mediated by an action on the P1-purinoceptor of smooth muscle. 5. It is evident from these results that in neonatal rat, a contractile response to ATP and ADP occurs initially in the duodenum, followed by a relaxant response to adenosine and AMP on day 14 and to ADP and ATP on day 21. 6. The smooth muscle of rat duodenum may tentatively be concluded to contain separate purinoceptors for adenosine and AMP (Pj) and ADP and ATP (P2) and the responses to P1- and P2-agonists change during the course of development.
Furukawa
K
K
Department of Pharmacology, Tokyo Women's Medical College, Japan.
Nomoto
T
T
D000227:Adenine Nucleotides / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000241:Adenosine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000255:Adenosine Triphosphate / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn / Q000502:physiology*; D004386:Duodenum / Q000187:drug effects / Q000254:growth & development; D005260:Female; D066298:In Vitro Techniques; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009126:Muscle Relaxation / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects*; D051381:Rats; D011919:Rats, Inbred Strains; D011983:Receptors, Purinergic / Q000187:drug effects*; D013779:Tetrodotoxin / Q000494:pharmacology; D013806:Theophylline / Q000031:analogs & derivatives / Q000494:pharmacology
D000227:Adenine Nucleotides; D011983:Receptors, Purinergic; D013779:Tetrodotoxin; D000255:Adenosine Triphosphate; D013806:Theophylline; C028322:8-phenyltheophylline; D000241:Adenosine